About iBET
iBET is a company based in Oeiras (Portugal) founded in 1989 by Manuel Carrondo. iBET offers products and services including Vaccine Development, Gene Therapy Products, and Bioprocess Engineering. iBET operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Oeiras, Portugal
- Founders Manuel Carrondo
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$13.64 K (USD), Grant
Feb 01, 2022
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of iBET
iBET offers a comprehensive portfolio of products and services, including Vaccine Development, Gene Therapy Products, and Bioprocess Engineering.
Research and production of vaccines for disease prevention
Advanced technologies for gene-based therapeutic solutions
Design of processes for cell-based therapies and drug discovery
People of iBET
Unlock access to complete
Funding Insights of iBET
Investors in iBET
iBET has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for iBET
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by iBET
Investment portfolio details for iBET
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - iBET
Detailed financials for iBET
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ibet Comparisons
Peer comparison for iBET
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of iBET
iBET operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of iBET
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ibet
Complete news archive for iBET
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iBET
iBET was founded in 1989 and raised its 1st funding round 25 years after it was founded.
iBET is headquartered in Oeiras, Portugal.
iBET was established in 1989 in Oeiras, Portugal, within the biotechnology sector. Genomics and analytical services are delivered by the company, supporting research and development in life sciences. Operations are centered in Portugal, with a focus on advanced analytical techniques and genomic applications for various industries. The founder and vice president role is held by Manuel Carrondo, guiding strategic initiatives in this field.
iBET's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
iBET offers Vaccine Development, Gene Therapy Products, and Bioprocess Engineering.
iBET has 1 investor. Key investors include European Union.